Expertise in
28
conditions

Dr. Michael Cohenuram

Oncology
Arthritis And Internal Medicine Associates LLC
5520 Park Ave, 
Trumbull, CT 
Offers Telehealth
Expertise in
28
conditions
Arthritis And Internal Medicine Associates LLC
5520 Park Ave, 
Trumbull, CT 

Overview

Michael Cohenuram is an Oncologist in Trumbull, Connecticut. Dr. Cohenuram is highly rated in 28 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC).

His clinical research consists of co-authoring 1 peer reviewed article and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in CT

Hospital Affiliations

Yale-New Haven Hospital
Bridgeport Hospital
Greenwich Hospital Association -
Griffin Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Chinese Community Health
  • HMO
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Arthritis and Internal Medicine Associates LLC
5520 Park Ave, Trumbull, CT 06611
Other Locations
Medical Oncology & Hematology PC
350 Seymour Ave Ste 6, Derby, CT 06418

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
View 4 Less Clinical Trials

1 Total Publications

Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab.
Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab.
Journal: Clinical lung cancer
Published: April 20, 2021
Similar Doctors
Expertise in
25
conditions
Dr. Masoud Azodi
Oncology
Expertise in
25
conditions
Dr. Masoud Azodi
Oncology

Bridgeport Hospital

267 Grant St, 
Bridgeport, CT 
 (4.8 miles away)
203-384-4870
Languages Spoken:
English
See accepted insurances

Masoud Azodi is an Oncologist in Bridgeport, Connecticut. Dr. Azodi is highly rated in 25 conditions, according to our data. His top areas of expertise are Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, Hysterectomy, and Endoscopy.

Expertise in
16
conditions
Dr. Scott Gettinger
Oncology
Expertise in
16
conditions
Dr. Scott Gettinger
Oncology

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (16.8 miles away)
203-200-5864
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Gettinger is an Oncologist in New Haven, Connecticut. Dr. Gettinger is highly rated in 16 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery.

Expertise in
32
conditions
Dr. Elena Ratner
Oncology
Expertise in
32
conditions
Dr. Elena Ratner
Oncology

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (16.8 miles away)
203-785-7385
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elena Ratner is an Oncologist in New Haven, Connecticut. Dr. Ratner is highly rated in 32 conditions, according to our data. Her top areas of expertise are Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, Oophorectomy, and Hysterectomy.

Frequently Asked Questions about Dr. Michael Cohenuram

How do I make an appointment with Dr. Michael Cohenuram?

You can book an appointment with Dr. Michael Cohenuram by calling their office at 203-502-8400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael Cohenuram a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael Cohenuram is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael Cohenuram specialize in?

While Dr. Michael Cohenuram is a Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Lung Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Michael Cohenuram participate in research or clinical trials?

Yes. Dr. Michael Cohenuram has published 1 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Michael Cohenuram's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael Cohenuram accept my insurance?

Dr. Michael Cohenuram accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 203-502-8400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cohenuram's expertise for a condition
ConditionClose
    View All 17 Distinguished Conditions
    View All 11 Advanced Conditions
    View All 91 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile